Search results
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 1 day agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
Zacks via Yahoo Finance· 9 hours agoCyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects,...
Covenant Logistics shares retain Buy rating on freight portfolio diversification By Investing.com
Investing.com· 8 hours agoOn Thursday, Covenant Logistics Group Inc. (NASDAQ:CVLG) maintained its Buy rating and $65.00 stock...
Ipsen shares maintain buy rating on drug data By Investing.com
Investing.com· 8 hours agoOn Thursday, Citi reaffirmed its Buy rating and €130.00 stock price target for Ipsen SA (IPN:FP)...
Buy These 5 Value Stocks With High Earnings Yield Now
Zacks via Yahoo Finance· 6 hours agoAverage Daily Volume (20 Days) greater than or equal to 100,000: High trading volume implies that a...
BofA acknowledges Citigroup's decision to de-risk the bank, keeps stock buy-rated By Investing.com
Investing.com· 7 hours agoOn Thursday, BofA Securities maintained a positive outlook on Citigroup Inc. (NYSE:C), reiterating a...
All You Need to Know About Reliance (RS) Rating Upgrade to Strong Buy
Zacks via Yahoo Finance· 9 hours agoReliance (RS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about...
Canaccord keeps Lyft at Buy with $23 target post-Investor Day By Investing.com
Investing.com· 6 hours agoOn Thursday, Canaccord Genuity upheld its Buy rating on shares of Lyft (NASDAQ:LYFT) with a steady...
2 Stocks to Buy After The European Central Bank & Bank of Canada Cut Rates
Zacks via Yahoo Finance· 3 hours agoPresumably, investors may be eyeing stocks that can benefit more directly from what will likely be a...
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
Zacks· 20 hours agoFree Report) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...